A detailed history of Ubs Asset Management Americas Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 198,256 shares of MYGN stock, worth $2.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
198,256
Previous 179,810 10.26%
Holding current value
$2.65 Million
Previous $4.4 Million 23.37%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.97 - $28.6 $442,150 - $527,555
18,446 Added 10.26%
198,256 $5.43 Million
Q2 2024

Aug 13, 2024

BUY
$17.98 - $25.47 $1.55 Million - $2.2 Million
86,439 Added 92.58%
179,810 $4.4 Million
Q3 2023

Nov 13, 2023

BUY
$15.99 - $23.22 $111,354 - $161,704
6,964 Added 8.06%
93,371 $1.5 Million
Q1 2023

May 15, 2023

BUY
$15.26 - $23.75 $216,615 - $337,131
14,195 Added 19.66%
86,407 $2.01 Million
Q4 2022

Feb 14, 2023

SELL
$14.51 - $20.99 $36,942 - $53,440
-2,546 Reduced 3.41%
72,212 $1.05 Million
Q3 2022

Nov 14, 2022

SELL
$18.21 - $27.88 $38,641 - $59,161
-2,122 Reduced 2.76%
74,758 $1.43 Million
Q2 2022

Aug 12, 2022

SELL
$16.45 - $25.88 $502,498 - $790,556
-30,547 Reduced 28.44%
76,880 $1.4 Million
Q1 2022

May 16, 2022

SELL
$22.67 - $28.01 $5,191 - $6,414
-229 Reduced 0.21%
107,427 $2.71 Million
Q4 2021

Feb 14, 2022

SELL
$24.13 - $32.63 $97,026 - $131,205
-4,021 Reduced 3.6%
107,656 $2.97 Million
Q3 2021

Nov 15, 2021

BUY
$29.97 - $36.66 $353,256 - $432,111
11,787 Added 11.8%
111,677 $3.61 Million
Q2 2021

Aug 16, 2021

BUY
$25.39 - $32.61 $484,491 - $622,264
19,082 Added 23.61%
99,890 $3.05 Million
Q1 2021

May 14, 2021

BUY
$19.92 - $31.6 $76,851 - $121,912
3,858 Added 5.01%
80,808 $2.46 Million
Q4 2020

Mar 01, 2021

SELL
$12.16 - $19.77 $35,069 - $57,016
-2,884 Reduced 3.61%
76,950 $1.52 Million
Q2 2020

Aug 14, 2020

SELL
$10.69 - $16.49 $149,050 - $229,920
-13,943 Reduced 14.87%
79,834 $905,000
Q1 2020

May 15, 2020

SELL
$9.78 - $29.53 $32,880 - $99,279
-3,362 Reduced 3.46%
93,777 $1.34 Million
Q4 2019

Feb 14, 2020

BUY
$20.93 - $35.1 $33,969 - $56,967
1,623 Added 1.7%
97,139 $2.65 Million
Q3 2019

Nov 14, 2019

BUY
$22.08 - $47.08 $243,409 - $519,009
11,024 Added 13.05%
95,516 $2.73 Million
Q2 2019

Aug 15, 2019

BUY
$22.67 - $35.0 $262,427 - $405,160
11,576 Added 15.88%
84,492 $0
Q1 2019

May 14, 2019

BUY
$26.93 - $34.7 $425,844 - $548,711
15,813 Added 27.69%
72,916 $0
Q4 2018

Feb 13, 2019

BUY
$27.23 - $45.56 $234,613 - $392,544
8,616 Added 17.77%
57,103 $1.66 Million
Q3 2018

Nov 14, 2018

BUY
$37.57 - $50.34 $180,711 - $242,135
4,810 Added 11.01%
48,487 $0
Q2 2018

Aug 14, 2018

SELL
$27.75 - $40.17 $228,965 - $331,442
-8,251 Reduced 15.89%
43,677 $0
Q1 2018

May 14, 2018

BUY
$28.83 - $41.01 $28,080 - $39,943
974 Added 1.91%
51,928 $0
Q4 2017

Feb 09, 2018

BUY
$28.45 - $37.14 $74,396 - $97,121
2,615 Added 5.41%
50,954 $0
Q3 2017

Nov 13, 2017

BUY
$24.01 - $36.2 $1.16 Million - $1.75 Million
48,339
48,339 $0

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.08B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.